SAN RAFAEL, Calif.,
July 9, 2018 /PRNewswire/
-- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today
announced an exclusive partnership with Believe Limited to produce
the 'Breaking Through!' musical theater intensive. The
first-of-its-kind program is a three-day music workshop for the
bleeding disorders community and is designed to provide young
adults with powerful education on the healing and therapeutic power
of the arts and self-expression. The musical workshop, directed by
hemophilia advocate and Believe Limited CEO Patrick James Lynch, will be held from
November 9 – November 12, 2018 and will culminate in a
Broadway-style performance for local bleeding disorder community
members, family and friends.
Twenty-five young adults from across the country will be
selected for the workshop to be held in New York City to learn and perform a six-song
musical about the psychosocial and general health aspects of being
a young person with a bleeding disorder. The songs and material
will be custom written by composers and lyricists based on ideas
shared directly from the participants during the application
process. High school students in the U.S. with hemophilia, who are
carriers of hemophilia, who have von Willebrand disease, who have
another rare factor deficiency, or who have a sibling living with a
bleeding disorder are invited to audition.1
Renowned vocal coach and director of UK Haemophilia Society
choir Paul Russell will work with
the selected high school students as the musical director. In
addition to musical performance, trained facilitators will conduct
breakout sessions for the participants on the impact of breathing
and relaxation pain management, the psychosocial benefits of and
the therapeutic value of self-expression in the arts.
"The 'Breaking Through!' musical theater intensive is a
groundbreaking effort to empower young people in the bleeding
disorder community who want to better understand how the arts and
artistic expression can improve their health outcomes, and really,
their lives in general," said Lynch. "We're breaking through the
barriers created by a bleeding disorder mentally, emotionally and
imaginatively with the arts. Our community does an incredible job
of working to inspire our young people to participate in physical
activity, but I believe it's as important to connect young people
to the health and wellness benefits that the arts and
self-expression offers as well."
"BioMarin is proud to support the next generation of the
bleeding disorder community by creating a positive and impactful
experience to allow teens to express the aspects of bleeding
disorders that are often overlooked, as well as raise awareness of
their impact on patient lives," said Hank
Fuchs, M.D., President, Worldwide Research and Development
at BioMarin.
Submissions are open now through September 1, 2018. Nominate a high school
student, apply or read more information here.
About Hemophilia A
Hemophilia A, also called factor VIII (FVIII) deficiency or
classic hemophilia, is a genetic disorder caused by missing or
defective factor VIII, a clotting protein. Although it is passed
down from parents to children, about 1/3 of cases are caused by a
spontaneous mutation, a new mutation that was not inherited.
Approximately 1 in 10,000 people is born with Hemophilia
A. People living with the disease are not able to form blood
clots efficiently and are at risk for excessive bleeding from
modest injuries, potentially endangering their lives. People with
severe hemophilia often bleed spontaneously into their muscles or
joints. The standard of care for the 43 percent of individuals with
hemophilia A who are severely affected is a prophylactic regimen of
Factor VIII infusions two to three times per week. Even with
prophylactic regimens, many people still experience spontaneous
bleeding events that result in progressive and debilitating joint
damage.
About Believe Limited
Believe Limited is an award-winning boutique agency focused on
creating educational, inspirational and deeply impactful digital
content, live events, podcasts and more for rare disease
communities, with a deeply-rooted focus in hemophilia and bleeding
disorders. Our work has been honored by the National Hemophilia
Foundation (NHF), Hemophilia Federation of America (HFA) and the
WEBBYs. To learn more about our content and programming, please
visit www.BelieveLTD.com.
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for people with serious and
life-threatening rare disorders. The company's portfolio consists
of six commercialized products and multiple clinical and
pre-clinical product candidates.
For additional information, please visit www.BMRN.com.
Information on BioMarin's website is not incorporated by reference
into this press release.
BioMarin® is a registered trademark of BioMarin Pharmaceutical
Inc.
1 No consideration will be given to whether
or not an applicant was previously or is currently undergoing
treatment with a BioMarin product
Contact:
|
|
|
Investors:
|
Media:
|
|
Traci
McCarty
|
Debra
Charlesworth
|
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
|
(415)
455-7558
|
(415)
455-7451
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/biomarin-partners-with-believe-limited-for-breaking-through-musical-theater-intensive-300677452.html
SOURCE BioMarin Pharmaceutical Inc.